Physician profile
Ross D Nochimson
NPI 1023157500
$7,527.15
in general payments reported to CMS, 2019-2025
36 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $1,699 · 2021: $1,712 · 2022: $1,095 · 2023: $904 · 2024: $795 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,231.09 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $760.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $725.64 | 2020-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $519.68 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $436.98 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $378.12 | 2019-2022 | |
| Lilly USA, LLC | $361.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.72 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $309.23 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $298.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.93 | 2019-2023 | Jardiance |
| Pfizer INC. | $270.75 | 2019-2025 | |
| Allergan, INC. | $217.73 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $199.91 | 2020-2021 | |
| Radius Health, INC. | $199.01 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $162.33 | 2021-2025 | |
| Abbvie INC. | $149.23 | 2021-2022 | |
| Edwards Lifesciences Corporation | $110.10 | 2024 | |
| Mylan Specialty L.P. | $71.41 | 2020-2021 | |
| Redhill Biopharma INC. | $56.11 | 2020 | |
| Sunovion Pharmaceuticals INC. | $53.98 | 2019-2020 | |
| Exact Sciences Corporation | $51.77 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $49.68 | 2021-2023 | Nuzyra |
| Saluda Medical Americas, INC. | $48.75 | 2025 | Evoke |
| Esperion Therapeutics, INC. | $36.14 | 2025 | Nexletol |
| Dexcom, INC. | $31.71 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.14 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.02 | 2019 | |
| Alfasigma USA, INC. | $25.20 | 2020 | |
| Astellas Pharma US INC | $17.62 | 2020 | |
| Nevro Corp. | $16.30 | 2022 | |
| Bausch Health US, LLC | $15.44 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.97 | 2022 | |
| Axsome Therapeutics, INC. | $14.22 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $12.74 | 2019 | |
| Corcept Therapeutics | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Nochimson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.